Microbiologist, I believe the generics recognized the possibility of AMRN’s success in REDUCEIT and have always had their eye on that potential pie. They weren’t interested in Marine indication except as a way to be able to sell into the CVD market if REDUCEIT Succeeded. It cost them next to nothing to challenge via ANDA. The upside is either a financial jackpot and favorable terms for early entry or the ultimate goal, win and, using willful blindness to the HW generic scheme, bypass the REDUCEIT patents and take over the CVD market. I agree that they probably expected to either settle on favorable terms or lose in court. I think the thought of winning was a long shot for them. Contracting for supply in anticipation of winning would have been foolish and expensive, if it was even possible. The expense to increase manufacturing capabilities and secure supply to meet 100k scripts a week was not financially feasible prior to winning in Nevada. They unexpectedly won and the rest is history. IMO.
Market Data 
Markets 
AI
